Satellos Bioscience (NASDAQ:MSLE) Announces Earnings Results

Satellos Bioscience (NASDAQ:MSLE) announced its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09), Zacks reports.

Satellos Bioscience Stock Down 2.2%

Satellos Bioscience stock traded down $0.15 during mid-day trading on Thursday, hitting $6.60. 24,457 shares of the company’s stock were exchanged, compared to its average volume of 56,029. The firm has a market capitalization of $140.03 million, a P/E ratio of -3.44 and a beta of 1.63. Satellos Bioscience has a fifty-two week low of $5.30 and a fifty-two week high of $13.39. The company’s 50 day simple moving average is $7.86 and its 200-day simple moving average is $8.21.

Analyst Upgrades and Downgrades

MSLE has been the subject of a number of recent analyst reports. Zacks Research downgraded Satellos Bioscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 21st. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Satellos Bioscience in a report on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Wednesday, November 4th. Finally, Craig Hallum assumed coverage on Satellos Bioscience in a research report on Thursday, October 8th. They set a “buy” rating and a $24.00 target price for the company. Six research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $20.60.

Satellos Bioscience Company Profile

Satellos Bioscience Inc. is a biotechnology company focused on developing regenerative medicines for muscle-related diseases and disorders. The company’s research centers on muscle satellite cells, a type of stem cell responsible for repairing and regenerating skeletal muscle after injury or disease. Satellos is developing small-molecule therapies intended to restore or enhance the natural muscle-regeneration process by correcting impaired satellite-cell function. Its lead program, SAT-3247, is being investigated as an orally administered potential treatment for muscle-wasting conditions, including Duchenne muscular dystrophy.